Overview

Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination

Status:
Completed
Trial end date:
2016-04-11
Target enrollment:
Participant gender:
Summary
This is a Phase 1, Single and Multiple-Dose, Open-Label Study in Healthy Subjects to Assess the Effect of the Acid Reducing Agents, Omeprazole and Famotidine, on the PK of CVC
Phase:
Phase 1
Details
Lead Sponsor:
Tobira Therapeutics, Inc.
Treatments:
Cenicriviroc
Famotidine
Omeprazole
TAK-652